Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Epigenetic inactivation of the miR-34a in hematological malignancies.

Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R.

Carcinogenesis. 2010 Apr;31(4):745-50. doi: 10.1093/carcin/bgq033. Epub 2010 Jan 29. Erratum in: Carcinogenesis. 2014 Nov;35(11):2631.

PMID:
20118199
2.

Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, Li GK, Jin DY, Chim CS.

PLoS One. 2011 Apr 22;6(4):e19027. doi: 10.1371/journal.pone.0019027.

3.

Epigenetic inactivation of the MIR129-2 in hematological malignancies.

Wong KY, Yim RL, Kwong YL, Leung CY, Hui PK, Cheung F, Liang R, Jin DY, Chim CS.

J Hematol Oncol. 2013 Feb 14;6:16. doi: 10.1186/1756-8722-6-16.

4.

Epigenetic inactivation of the hsa-miR-203 in haematological malignancies.

Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L.

J Cell Mol Med. 2011 Dec;15(12):2760-7. doi: 10.1111/j.1582-4934.2011.01274.x.

5.

Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.

Wang LQ, Kwong YL, Wong KF, Kho CS, Jin DY, Tse E, Rosèn A, Chim CS.

J Transl Med. 2014 Feb 22;12:52. doi: 10.1186/1479-5876-12-52.

6.

Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.

Ng HY, Wan TS, So CC, Chim CS.

J Clin Pathol. 2014 Jul;67(7):626-31. doi: 10.1136/jclinpath-2014-202276. Epub 2014 May 7.

PMID:
24811488
7.

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.

Wang LQ, Kwong YL, Kho CS, Wong KF, Wong KY, Ferracin M, Calin GA, Chim CS.

Mol Cancer. 2013 Dec 27;12:173. doi: 10.1186/1476-4598-12-173.

8.

Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms.

Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF.

J Transl Med. 2011 Nov 14;9:197. doi: 10.1186/1479-5876-9-197.

10.

Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.

Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW.

Carcinogenesis. 2007 Jan;28(1):60-70. Epub 2006 Jun 14.

PMID:
16774933
11.

Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.

Cui X, Zhao Z, Liu D, Guo T, Li S, Hu J, Liu C, Yang L, Cao Y, Jiang J, Liang W, Liu W, Li S, Wang L, Wang L, Gu W, Wu C, Chen Y, Li F.

J Exp Clin Cancer Res. 2014 Feb 17;33:20. doi: 10.1186/1756-9966-33-20.

12.

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J, Hermeking H.

Cell Cycle. 2008 Aug 15;7(16):2591-600. Epub 2008 Aug 1.

PMID:
18719384
13.

The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).

Yan-Fang T, Jian N, Jun L, Na W, Pei-Fang X, Wen-Li Z, Dong W, Li P, Jian W, Xing F, Jian P.

BMC Med Genet. 2013 Jul 19;14:74. doi: 10.1186/1471-2350-14-74.

14.

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.

Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.

Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19.

PMID:
22810507
15.

Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.

Zheng Z, Takahashi M, Aoki S, Toba K, Liu A, Osman Y, Takahashi H, Tsukada N, Suzuki N, Nikkuni K, Furukawa T, Koike T, Aizawa Y.

J Exp Clin Cancer Res. 1998 Sep;17(3):251-8.

PMID:
9894758
16.

Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Yim RL, Wong KY, Kwong YL, Loong F, Leung CY, Chu R, Lam WW, Hui PK, Lai R, Chim CS.

Oncotarget. 2014 Oct 30;5(20):9770-82.

17.

Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.

Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G.

Exp Hematol. 2001 Feb;29(2):228-33.

PMID:
11166462
18.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R.

Blood. 2010 May 27;115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.

19.

miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M.

Carcinogenesis. 2009 Nov;30(11):1903-9. doi: 10.1093/carcin/bgp219. Epub 2009 Sep 7.

PMID:
19736307
20.

Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.

Zhang Q, Wang LQ, Wong KY, Li ZY, Chim CS.

J Clin Pathol. 2015 Jul;68(7):557-61. doi: 10.1136/jclinpath-2014-202817. Epub 2015 Apr 8.

PMID:
25855800

Supplemental Content

Support Center